MCID: CHL009
MIFTS: 17

Childhood Cerebral Astrocytoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Childhood Cerebral Astrocytoma

MalaCards integrated aliases for Childhood Cerebral Astrocytoma:

Name: Childhood Cerebral Astrocytoma 12 53 73
Pediatric Astrocytoma of Cerebrum 12
Cerebral Astrocytoma, Childhood 53

Classifications:



External Ids:

Disease Ontology 12 DOID:7007
MeSH 44 D001254
NCIt 50 C4347
UMLS 73 C0338070

Summaries for Childhood Cerebral Astrocytoma

MalaCards based summary : Childhood Cerebral Astrocytoma, is also known as pediatric astrocytoma of cerebrum. The drugs Carboplatin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and bone.

Related Diseases for Childhood Cerebral Astrocytoma

Symptoms & Phenotypes for Childhood Cerebral Astrocytoma

Drugs & Therapeutics for Childhood Cerebral Astrocytoma

Drugs for Childhood Cerebral Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 193)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
2
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
3
Etoposide Approved Phase 3,Phase 1,Phase 2,Not Applicable 33419-42-0 36462
4
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1 4342-03-4 5351166
5
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1 85622-93-1 5394
6
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
7
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
8
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
9
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
10
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
11
Vincristine Approved, Investigational Phase 3,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
12
Thioguanine Approved Phase 3 154-42-7 2723601
13
Procarbazine Approved, Investigational Phase 3,Phase 1 671-16-9 4915
14
Lomustine Approved, Investigational Phase 3,Phase 1 13010-47-4 3950
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
16
Ondansetron Approved Phase 3 99614-02-5 4595
17
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
19
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
20
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
21
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
22 Adjuvants, Immunologic Phase 3,Phase 1,Not Applicable
23 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
24 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
25 Alkylating Agents Phase 3,Phase 2,Phase 1
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Dermatologic Agents Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
29 Etoposide phosphate Phase 3,Phase 1,Phase 2,Not Applicable
30 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
31 Histone Deacetylase Inhibitors Phase 2, Phase 3,Phase 1
32 Antibodies Phase 2, Phase 3,Phase 1
33 Immunoglobulins Phase 2, Phase 3,Phase 1
34 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
35 Endothelial Growth Factors Phase 2, Phase 3
36 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
37 Immunoglobulin G Phase 2, Phase 3
38 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
39 Mitogens Phase 2, Phase 3,Phase 1
40 Antimetabolites Phase 3,Phase 2
41 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Antimetabolites, Antineoplastic Phase 3,Phase 2
43 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Antiemetics Phase 3,Phase 1
45 Autonomic Agents Phase 3,Phase 1
46 BB 1101 Phase 3,Phase 2,Phase 1
47 Peripheral Nervous System Agents Phase 3,Phase 1
48 Emetics Phase 3
49 Serotonin Agents Phase 3,Phase 2
50 Anti-Allergic Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
2 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
3 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
4 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Magnetic Resonance Imaging in Treating Children With Progressive Low-Grade Astrocytoma Unknown status NCT00005084 Phase 2
7 Radiation Therapy in Treating Young Patients With Gliomas Unknown status NCT00238264 Phase 2
8 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
9 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
10 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
11 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
12 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
13 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
14 Lobradimil and Carboplatin in Treating Children With Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
15 Vinorelbine in Treating Children With Recurrent or Refractory Cancers Completed NCT00003234 Phase 2 vinorelbine tartrate
16 Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00003241 Phase 2 phenylacetate
17 Carboplatin in Patients With Progressive Gliomas Completed NCT00002749 Phase 2 carboplatin
18 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
19 Docetaxel in Treating Children With Recurrent Solid Tumors Completed NCT00002825 Phase 2 docetaxel
20 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
21 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
22 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
23 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
24 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
25 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
26 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
27 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
28 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
29 Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma Terminated NCT00021229 Phase 1, Phase 2 imatinib mesylate
30 TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma Terminated NCT00074334 Phase 1, Phase 2
31 Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma Unknown status NCT00052624 Phase 1
32 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
33 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
34 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
35 Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma Completed NCT00107185 Phase 1
36 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
37 Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
38 Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Completed NCT00012181 Phase 1 alvocidib
39 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
40 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
41 Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors Completed NCT00077454 Phase 1 erlotinib hydrochloride;temozolomide
42 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
43 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
44 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
45 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
46 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
47 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
48 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
49 Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Completed NCT00352495 Phase 1 carboplatin;vinblastine sulfate
50 Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate

Search NIH Clinical Center for Childhood Cerebral Astrocytoma

Genetic Tests for Childhood Cerebral Astrocytoma

Anatomical Context for Childhood Cerebral Astrocytoma

MalaCards organs/tissues related to Childhood Cerebral Astrocytoma:

41
Brain, Liver, Bone

Publications for Childhood Cerebral Astrocytoma

Variations for Childhood Cerebral Astrocytoma

Expression for Childhood Cerebral Astrocytoma

Search GEO for disease gene expression data for Childhood Cerebral Astrocytoma.

Pathways for Childhood Cerebral Astrocytoma

GO Terms for Childhood Cerebral Astrocytoma

Sources for Childhood Cerebral Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....